Related Experiment Video
Updated: May 17, 2025

09:54
Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
Published on: December 3, 2019
8.9K
Tamdy virus pathogenesis in immunocompetent and immunocompromised mouse models
Mingxue Cui1, Hua-Chen Zhu2, Xiurong Wang1
1School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Ji'nan, China.
Virulence
|May 12, 2025
Summary
Tamdy virus (TAMV) pathogenesis was investigated using mouse models. Type I interferon receptor knockout (IFNAR-/-) mice showed susceptibility to TAMV, revealing severe liver damage and informing antiviral and vaccine development.
Area of Science:
- Virology
- Immunology
- Pathogenesis Research
Background:
- Tamdy virus (TAMV) is an emerging zoonotic tick-borne bunyavirus posing global public health risks.
- Understanding TAMV pathogenesis is crucial for developing effective countermeasures.
Purpose of the Study:
- To establish and utilize mouse infection models for investigating TAMV pathogenesis.
- To elucidate the clinical and pathological outcomes of TAMV infection in different mouse strains.
Main Methods:
- Infection of adult BALB/c and type I interferon receptor knockout (IFNAR-/-) A129 mice with TAMV.
- Monitoring of clinical symptoms, viral load in blood and tissues, and pathological examination.
- Analysis of host immune responses, including antibody titers, cytokine/chemokine expression, and gene ontology.
Main Results:
- BALB/c mice showed no obvious symptoms, while A129 mice exhibited severe illness, weight loss, and mortality at high TAMV doses.
- High viral loads and significant liver damage were observed in infected A129 mice.
- TAMV infection induced rapid increases in IgM and IgG titers, with type I IFN potentially enhancing IL-10 production for host defense.
Conclusions:
- Immunocompromised A129 mice are a valuable model for studying TAMV pathogenesis.
- Liver injury is linked to virus-induced inflammatory responses.
- These findings provide a foundation for developing TAMV-specific antivirals and vaccines.

